Cevostamab is a bispecific antibody that targets FcRH5, a protein expressed in B-cell malignancies and multiple myeloma cells. It is specifically located on the 1q chromosome.

Cevostamab Clinical Trials (July 2024)

NCT05801939: Cevostamab Following CAR T-Cell Therapy in Relapsed/Refractory Myeloma

• This Phase 2 study is for relapsed/refractory multiple myeloma patients who received a CAR T-cell infusion.
• The purpose of this study is to assess the impact of cevostamab consolidation after a BCMA-targeted CAR T-cell therapy on the rate of minimal residual disease (MRD) negative complete remission (CR) at 12 months.
• Status: Actively Recruiting (as of July 2024)

NCT03275103: Cevostamab Dosing and Safety Trial 

• This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).
• Status: Actively Recruiting (as of July 2024)

NCT05535244: Efficacy and Safety of Cevostamab in Prior BCMA-Targeting Exposed Patients with Relapsed/Refractory Myeloma 

• This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
• Patients who have received BCMA-directed therapy are qualified to join. 
• Status: Actively Recruiting (as of July 2024)

For more or updated information on these clinical trials, check out our HealthTree Myeloma Clinical Trial Finder. 

Learn more about cevostamab

Interview filmed at EHA in June 2024.